Drug Trial Radar · NCT07088458
An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Children With Hemophilia A
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 16, 2026
Primary completion
Dec 31, 2029
Study completion Mar 1, 2030
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jul 28, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 7 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational study of children with mild, moderate, or severe hemophilia A who are receiving damoctocog alfa pegol, and are between 7 to \<12 years of age at the time of enrolment. Observational studies use data that are collected as part of routine medical care and participants do not receive any advice or any changes to healthcare as part of the study. In this study, the data will be collected from participants who are starting or already receiving damoctocog alfa pegol as prescribed by their doctor. Participants taking part may have received factor 8 (FVIII) treatment before. The study may also include participants who have never received factor 8 treatment or who have received it only a few times. Hemophilia A is a genetic bleeding disorder. It is caused by the lack of a protein called clotting factor 8 (FVIII) that helps blood to clot properly. Lack of FVIII can result in excessive blood loss or bleeding inside the body after being injured or having surgery. At times, there is spontaneous bleeding into the joint spaces that leads to joint damage. The drug observed in this study, damoctocog alfa pegol, is approved for doctors to prescribe to children who are at least 7 years old with hemophilia A. It is used to prevent or treat bleeding episodes and works by replacing missing FVIII in the body of people with hemophilia A. The participants will receive damoctocog alfa pegol as prescribed independently by their own doctors during routine practice, not as a part of the study. Participants may choose to enroll in the study at any time after their doctor has prescribed damoctocog alfa pegol to prevent bleeding episodes. The main purpose of this study is to learn more about how a treatment with damoctocog alfa pegol works to prevent bleeding episodes in routine medical practice. To answer this question, doctors will collect: * information about bleeding episodes including the type and the location of the bleed * information about the treatment with damoctocog alfa pegol and other FVIII products * the overall health status of the participants Data will be collected from participants over two years after they enroll in the study or until they choose to leave the study or switch to another hemophilia A treatment. Historical data will come from the participants' medical records or by interviewing the patient and parent/ legal guardian. The children's parents/ guardians will be asked to maintain a health diary to record details of bleeding episodes and treatment with damoctocog alfa pegol. The children's parents/ guardians will also be asked to answer a questionnaire (PedHAL) to assess the effect of hemophilia on their child's functional and physical activities. In this study, only available data from routine care will be collected. No additional visits or tests are required as part of this study.
Conditions
- Hemophilia A
Interventions
Damoctocog alfa pegol (Jivi, Bay94-9027)Drug
Follow clinical practice of BAY94-9027 to further define the treatment outcomes of damoctocog alfa pegol based on real-world use for regular prophylaxis in ages 7 to \<12 years, including a broader population and a real-world treatment patterns.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treated bleeds per individual diary documentation period while prescribed damoctocog alfa pegol prophylaxis (overall and by dosing regimen)Time frame: Up to 24 months
Locations
12 sites in 11 countries. Site status is shown where the registry gives one.
Loma Linda University Health
Loma Linda, California · Not yet recruiting
Rutgers, The State University
New Brunswick, New Jersey · Not yet recruiting
Many locations
Many Locations, Brazil · Not yet recruiting
Many locations
Many Locations, Canada · Withdrawn
Many locations
Many Locations, Colombia · Not yet recruiting
Many locations
Many Locations, Denmark · Not yet recruiting
Many locations
Many Locations, Italy · Not yet recruiting
Many locations
Many Locations, Japan · Not yet recruiting
Many locations
Many Locations, Lithuania · Recruiting
Many locations
Many Locations, Mexico · Not yet recruiting
Many locations
Many Locations, Norway · Not yet recruiting
Many locations
Many Locations, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.